Corneal Stromal Stem Cell Quality Screening for Scar Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need to improve the effectiveness of corneal stromal stem cells (CSSCs) in treating corneal scarring due to variations in stem cell stability and other measurable cell features.

Innovation Solution

The method involves obtaining a CSSC sample, measuring the expression of stemness markers for stability, creating a conditioned medium, introducing it into a cell-based inflammation model, calculating the inflammation ratio, and determining a scarring index score to assess the CSSC's effectiveness in reducing corneal scar formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cultivated CSSCs are applied in fibrin gel to injured corneal tissue, then anti-scarring and healing activity is achieved, but variations in effectiveness occur due to stem cell stability and measurable cell features

Engineering Contradiction:

Improveeffectiveness of CSSC therapyVSAvoidstem cell stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent performs preliminary quality screening of CSSC samples before clinical application by measuring stemness marker expression levels and calculating scarring index scores. This preliminary assessment identifies CSSCs with optimal healing capability, ensuring reliable therapeutic outcomes while accounting for variations in stem cell stability among different donor samples

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent establishes specific parameter thresholds for quality control, including minimum expression levels of stemness markers (ABCG2, NESTIN) and maximum scarring index scores. By defining these quantitative parameters, the patent standardizes CSSC quality assessment, enabling consistent selection of effective cell samples and reducing variability in therapeutic response

Inventive Principle:

Principle #35Parameter changes

2Reliability

If not every batch of donor-derived CSSCs shows suitable anti-scarring and healing activity, then quality control is needed, but additional screening steps increase time and resource requirements

Engineering Contradiction:

Improvequality consistency of CSSC batchesVSAvoidscreening time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent replaces complex in vivo testing or lengthy functional assays with a streamlined in vitro screening method based on stemness marker expression measurement and scarring index calculation. This substitution maintains quality control reliability while significantly reducing screening time and resource requirements, enabling rapid assessment of CSSC batches before clinical use

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS20250137995A1In vitro quality screening of human corneal stromal stem cells for cell-based therapy of corneal scarring

Publication Date: 2025.05.01 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

AI summary

The present disclosure relates to a method of determining effectiveness of corneal stromal stem cell therapy through evaluation of stem cell markers, inflammation markers, and assessing a scarring index.